AbbVie (ABBV) to Acquire Stemcentrx in ~$5.8B Cash and Stock Deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
AbbVie (ABBV) Tops Q1 EPS by 1c; Updates FY16 EPS Outlook
April 28, 2016 7:23 AM EDTAbbVie (NYSE: ABBV) reported Q1 EPS of $1.15, $0.01 better than the analyst estimate of $1.14. Revenue for the quarter came in at $5.96 billion versus the consensus estimate of $6.03 billion.
GUIDANCE:
AbbVie sees FY2016 EPS of $4.62-$4.82, versus the consensus of $4.97.
The company's 2016 adjusted... More
